Related Experiment Video
Updated: Aug 10, 2026
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.6K
Percutaneous micro-axial flow pump use during non-emergent high-risk PCI: Systematic review and meta-analysis
Hossam Elbenawi1, Mohamed Doma2, Busra Cangut3
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: https://twitter.com/ElbenawiH.
Summary
Percutaneous micro-axial flow pumps (mAFP) did not improve outcomes for high-risk PCI patients. Pre-procedure mAFP use was linked to increased bleeding and myocardial infarction risks, necessitating further research.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Percutaneous micro-axial flow pumps (mAFP) are increasingly utilized for hemodynamic support in high-risk percutaneous coronary interventions (PCI).
- Evidence supporting the effectiveness of mAFP in these procedures remains limited.
- This meta-analysis evaluates the efficacy and safety of mAFP during non-emergent high-risk PCI.
Purpose of the Study:
- To assess the effectiveness of percutaneous micro-axial flow pumps (mAFP) in reducing major adverse cardiac events (MACE) during non-emergent high-risk PCI.
- To evaluate the safety profile of mAFP use, including peri-procedural complications.
- To compare outcomes between patients receiving mAFP and control groups.
Main Methods:
- A meta-analysis was conducted, including eight studies (one randomized, seven observational) with 4688 patients.
- Studies compared percutaneous mAFP versus control for non-emergent high-risk PCI.
- The primary outcome was the incidence of major adverse cardiac events (MACE) within 30 days and at 1 year.
Main Results:
- No significant difference in MACE or mortality at 30 days or 1 year was observed between mAFP and control groups.
- Peri-procedural complications such as acute kidney injury, major bleeding, and stroke were not elevated with mAFP use.
- In patients receiving mAFP prior to PCI, higher in-hospital risks of major bleeding, blood transfusion, and myocardial infarction were noted.
Conclusions:
- Percutaneous micro-axial flow pump use did not demonstrate improved outcomes for patients undergoing non-emergent high-risk PCI.
- The study highlights potential increased risks of bleeding and myocardial infarction with pre-PCI mAFP use.
- Large-scale randomized trials are essential to definitively ascertain the efficacy and safety of mAFP, considering potential selection bias.
